Presented by ASBP: A small-cap biotech is rebuilding how medicine hits the bloodstream—delivering aspirin's full effect in minutes, not hours. See why ASBP's sublingual platform has multiple 2026 catalysts lining up →

This morning's tape is a study in what's driving stocks right now, and it isn't always fundamentals. The biggest gainer is running on pure Reddit momentum and short-squeeze math, while the memory complex bounces back from a selloff that had nothing to do with the companies themselves.

On the other side, beats aren't enough. A delivery giant topped estimates and still fell, and a freshly public AI name got hammered on soft margin guidance. The lesson today: the market cares far more about what comes next than what just happened.

Aspire Biopharma (NASDAQ: ASBP) emerges as a high-velocity biotech disruptor with fast-acting sublingual technology, an expanding pipeline, and commercial breakout potential across pharma and consumer health.

Aspire Biopharma (NASDAQ: ASBP) is rapidly evolving into a high-momentum biotech platform story built around a fundamentally disruptive approach to drug delivery. Its patent-pending sublingual technology is designed to bypass traditional digestive limitations and deliver therapeutics directly into the bloodstream with dramatically faster onset and improved bioavailability.

Clinical data from its lead high-dose sublingual aspirin program has already demonstrated therapeutic action in minutes rather than the delayed absorption profile of conventional oral tablets, signaling a potential shift in how acute-care and chronic therapies are administered.

What makes ASBP particularly compelling is not just a single asset, but a broader platform strategy. The Company is expanding into multiple high-value therapeutic areas including anti-anxiety, anti-nausea, and antiplatelet drugs while simultaneously building a growing intellectual property portfolio aimed at protecting its delivery mechanism across entire drug classes.

Combined with early commercial traction from BUZZ BOMB™ and improving financial flexibility, ASBP is beginning to shape a dual-path model that spans both pharmaceutical innovation and consumer health commercialization.

This is the type of setup that often attracts attention before broader market recognition sets in—where platform technology, early data validation, and expanding IP converge ahead of scale.

Discover how in a sector where many companies pursue narrow, single-asset strategies, ASBP’s multi-vector approach is beginning to stand out as something structurally different.

Wendy's (WEN): +21%

The fast-food chain is surging after becoming one of the most-discussed names. With short interest sitting around 23% of float, retail traders are betting on a potential short squeeze. This is a sentiment-driven move, not a fundamentals story, and that is exactly what makes it worth watching.

Micron (MU): +5%

The memory stock is rebounding after a sharp 13% drop on Tuesday, and it is climbing into its own earnings report due after the bell. Traders appear to be positioning ahead of results that could set the tone for the entire memory complex.

Arm Holdings (ARM): +4%

The chip-design company picked up price target hikes from both UBS and TD Cowen. Both firms see its CPU business improving as agentic AI drives demand toward Arm's architecture, a clean read-through on where the next leg of the AI trade is headed.

Sandisk (SNDK): +3%

The memory maker is rising alongside Micron as the broader group recovers from Tuesday's selloff, which was triggered by a slide in South Korean tech stocks. When the whole complex moves together like this, it signals the selloff was about sentiment, not company-specific trouble. Peers Western Digital and Seagate are higher as well.

Take-Two Interactive (TTWO): +3%

Shares are up after the company set Grand Theft Auto 6 presales to begin Thursday, and BTIG initiated coverage with a buy rating. BTIG's view is that the game drives a multi-year step-up in earnings power, framing GTA 6 as a long-term catalyst rather than a one-quarter event.

Worthington Enterprises (WOR): -10%

The industrial manufacturer missed on both earnings and revenue last quarter. For a steady industrial name, a clean double miss is enough to send investors heading for the exits.

Cerebras Systems (CBRS): -8%

The AI chipmaker dropped in its first earnings report since going public in May. The bigger problem than the headline loss is guidance: management expects gross margins to compress meaningfully next quarter, and for a freshly public AI name priced for perfection, any sign of margin pressure gets punished hard.

FedEx (FDX): -7%

Shares are falling even after the delivery giant beat on its fiscal fourth quarter. This was the last report before FedEx spins off its freight business, so the market may be looking through the beat toward the uncertainty of what the company looks like split in two.

Aspire Biopharma (NASDAQ: ASBP) is quietly turning a sublingual drug delivery breakthrough into a potential biotech scale-up story with multiple catalysts aligning in 2026!

Aspire Biopharma (NASDAQ: ASBP) is starting to look like one of those quietly building biotech stories that could get loud fast. At the center is its sublingual drug delivery tech—basically rethinking how fast medicine hits the bloodstream by bypassing the traditional digestive slowdown. 

Early clinical results with its high-dose sublingual aspirin are already showing absorption and platelet inhibition in minutes, not hours, which is a big deal in acute care scenarios where time isn’t just money—it’s survival.

What makes this even more interesting is that ASBP isn’t staying in one lane. The pipeline is branching into multiple high-demand therapeutics like anxiety, nausea, and antiplatelet treatments, all built on the same core delivery engine.

Add in expanding patents, a growing IP moat, and early consumer traction from BUZZ BOMB™ energy strips, and you’ve got a company operating like a biotech with startup speed and platform ambition. It’s still early, but the pieces are starting to stack in a way the broader market hasn’t fully priced in yet.

See how ASBP is one of those under-the-radar biotech setups worth watching closely—because if this platform clicks, it doesn’t stay under the radar for long!

Lucid Group (LCID)

Retail traders are circling Lucid after the EV maker announced a major restructuring on Monday: an 18% cut to its U.S. workforce, elimination of its second production shift, and the removal of its COO role. Chatter across r/wallstreetbets and StockTwits is split between bulls who see a leaner path to profitability and bears who read deep job cuts as a demand problem the company can't outrun.

Lucid says the plan should deliver roughly $158 million in annualized savings, with completion targeted for the end of Q3. With its sub-$50,000 Cosmos SUV still the make-or-break catalyst ahead, this restructuring could be the moment that either reframes the turnaround story or confirms the skeptics.